A method for treating diabetes

By adding IL-6 to bone marrow mesenchymal stem cells and implanting them into the animal, using their ability to regenerate the pancreatic exocrine glands in ectopic ways, the problem of poor effectiveness in treating type I diabetes was solved, and simplified cells were achieved Treatment process and significant blood sugar control effects.

CN114762725BActive Publication Date: 2024-11-05EV CELL BIOTECH GUANGZHOU CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202111641881.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-12-30
Filing Date
2021-12-29
Publication Date
2024-11-05
Estimated Expiration
2041-12-29

Smart Images

  • Figure CN114762725B_ABST
    Figure CN114762725B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biomedicine and relates to a method for treating diabetes. In the present invention, a composition containing IL-6 and bone marrow mesenchymal stem cells is provided for use in the preparation of a drug for treating / preventing diabetes. The inventors have found that the effect of bone marrow mesenchymal stem cells in treating type 1 diabetes is far less than that of mesenchymal stem cells derived from the exocrine glands of the pancreas, and that bone marrow mesenchymal stem cells are co-cultured (directly contacted) with pancreatic β cells, and bone marrow mesenchymal stem cells have a killing effect on pancreatic β cells. This results in bone marrow mesenchymal stem cells not being an ideal cell source for treating type 1 diabetes. However, the inventors are not limited to this status quo, but after continuous exploration and research, they found that after adding IL-6 to bone marrow mesenchymal stem cells, it was unexpectedly found that the effect of treating type 1 diabetes can be greatly improved. Thereby overcoming the technical obstacles of poor effect of bone marrow mesenchymal stem cells in treating type 1 diabetes and expanding the cell source for treating type 1 diabetes. Bone marrow mesenchymal stem cells, which are easier to obtain and have a wide range of sources than mesenchymal stem cells derived from the exocrine glands of the pancreas, can be used clinically. It has very good practical significance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine and relates to a method for treating diabetes. Background Art

[0002] Diabetes is a disease that develops from insufficient insulin and loss of its function. Once it develops into diabetes, it is difficult to cure. Diabetes can be mainly divided into two types: type I diabetes (insulin-dependent diabetes) and type II diabetes (non-insulin-dependent diabetes). Type II diabetes is a chronic disease that develops from insulin resistance. It becomes a problem related to lifestyle habits, such as obesity, stress, etc. caused by overeating and inactivity. Type II diabetes usually develops in middle-aged and elderly people, and many diabetic patients suffer from type II diabetes. Type I diabetes is a chronic disease caused by autoimmune diseases, viral infections, etc. that destroy pancreatic cells (also called insulin-producing cells) to stop insulin secretion in the body.

[0003] In recent years, the incidence of diabetes has been on the rise, and it is becoming younger. Diabetes has become a common endocrine metabolic disease that seriously endangers human health. Different types of diabetes will cause the beta cells in the pancreas to fail to produce enough insulin to lower blood sugar concentrations, leading to the occurrence of hyperglycemia. The current treatment method mainly uses drug therapy. Although drug therapy can lower blood sugar, it cannot cure diabetes. The use of insulin for treatment can control symptoms, but long-term use will produce insulin resistance. Islet transplantation surgery has low risks and is an effective means of curing diabetes, but the relative shortage of donors and immune rejection reactions after transplantation have seriously hindered the widespread application of this therapy. Diabetes has become a major public health problem due to its widespread prevalence and lack of cure. Summary of the invention

[0004] In some embodiments, a composition comprising IL-6 and mesenchymal stem cells is used in the preparation of a drug for treating / preventing diabetes.

[0005] In some embodiments, the source of the mesenchymal stem cells includes bone marrow, urine, oral cavity, fat, placenta, umbilical cord, periosteum, tendon, peripheral blood or pancreas.

[0006] In some embodiments, the mesenchymal stem cells are bone marrow-derived mesenchymal stem cells.

[0007] In some embodiments, the IL-6 and mesenchymal stem cells are administered simultaneously.

[0008] In some embodiments, the IL-6 and mesenchymal stem cells are administered separately.

[0009] In some embodiments, IL-6 is administered first, followed by the administration of mesenchymal stem cells.

[0010] In some embodiments, mesenchymal stem cells are administered first, followed by IL-6.

[0011] In some embodiments, the medicament is an injectable preparation.

[0012] In some embodiments, the drug is selected from intravenous injection, intramuscular injection, subcutaneous injection or intrathecal injection.

[0013] In some embodiments, the mesenchymal stem cells are injected into the kidney capsule.

[0014] In some embodiments, the IL-6 is administered by intraperitoneal injection.

[0015] In some embodiments, the medicament further comprises a pharmaceutically acceptable carrier.

[0016] In some embodiments, the pharmaceutical carrier includes one or more of a diluent, an excipient, a filler, a binder, a disintegrant, a surfactant, and a lubricant.

[0017] In some embodiments, the diabetes is type 1 diabetes.

[0018] The inventors have found that the effect of bone marrow mesenchymal stem cells in treating type 1 diabetes is far less effective than that of mesenchymal stem cells derived from the exocrine pancreatic glands, and that bone marrow mesenchymal stem cells are co-cultured with pancreatic β cells (direct contact), and bone marrow mesenchymal stem cells have a killing effect on pancreatic β cells. This has led to the fact that bone marrow mesenchymal stem cells are not an ideal cell source for treating type 1 diabetes. However, the inventors are not limited to this status quo, but through continuous exploration and research, they found that after adding IL-6 to bone marrow mesenchymal stem cells, they unexpectedly found that the effect of treating type 1 diabetes can be greatly improved. This overcomes the technical obstacle of poor effect of bone marrow mesenchymal stem cells in treating type 1 diabetes and expands the cell source for treating type 1 diabetes. This makes bone marrow mesenchymal stem cells, which are easier to obtain than mesenchymal stem cells derived from the exocrine pancreatic glands and have a wide range of sources, available for clinical use. It has very good practical significance.

[0019] In some embodiments, the present invention provides a system for treating / preventing diabetes, comprising mesenchymal stem cells and IL-6, and an implant device.

[0020] In some embodiments, the implantation device is used to implant mesenchymal stem cells into a specific site in a patient's body.

[0021] In some embodiments, the implantation device is a trocar.

[0022] In some embodiments, the targeted site includes subrenal capsule, subcutaneous tissue, or mesentery.

[0023] In some embodiments, the system further comprises an ultrasound device or an endoscopic device.

[0024] In some embodiments, the ultrasound device or the endoscopic device is used to guide the positioning of the implant device.

[0025] In some embodiments, the implantation is subrenal implantation.

[0026] In some embodiments, the present invention provides the use of a substance that promotes the formation of pancreatic exocrine glands in the preparation of a drug for treating / preventing diabetes, wherein the pancreatic exocrine glands are formed by ectopic regeneration and natural differentiation of mesenchymal stem cells derived from pancreatic exocrine glands.

[0027] The pancreas has endocrine glands (endocrine cells) and exocrine glands (exocrine cells), and is an organ that plays an important role in both secretory cells. Exocrine cells mainly play a role in secreting digestive enzymes such as pancreatic lipase, trypsin, elastase, and pancreatic amylase.

[0028] In some embodiments, the diabetes is type 1 diabetes.

[0029] In some embodiments, the location of ectopic regeneration includes subrenal capsule and subcutaneous.

[0030] Among them, the pancreatic β cells in patients with type 1 diabetes are necrotic and do not produce insulin. There is currently no cure. Recently, studies at home and abroad have reported that MSC can promote the regeneration of pancreatic islet cells. MSC transplantation is expected to become a new method for the treatment of diabetes, especially for the treatment of type 1 diabetes. In other words, it is generally believed that mesenchymal stem cells can achieve the effect of treating diabetes by regenerating pancreatic β cells. For example, in 2008, Song Zhenshun's team at the Tenth People's Hospital Affiliated to Tongji University found that pancreatic stem cells can differentiate into islet-like structures that secrete insulin, and sequential transplantation of islets and islet-like structures derived from pancreatic stem cells has a therapeutic effect on rat diabetes. They also found that MSC with multidirectional differentiation potential can also differentiate into insulin-producing cells (IPC) and vascular endothelial cells in vivo. Transplantation of MSC and IPC derived from them significantly promoted the formation of new blood vessels around the residual islets of the recipient, thereby causing the residual islets to proliferate. This study was confirmed by Barky et al. In addition, the study of Arzouni et al. also found that after MSC transplantation, human islet function can be improved by releasing annexin A1 (ANXA1) and extracellular matrix. Some studies have also shown that the co-transplantation of autologous MSCs and pancreatic islets can improve the success rate and safety of islet transplantation, effectively reduce allogeneic transplantation immune rejection and early graft loss caused by inflammatory response, or provide a new solution for the treatment of type 1 diabetes. For example, the study by Daisong Wang et al. mentioned that pancreatic progenitor cells can form islet-like tissue, in which pancreatic β cells account for the majority of the tissue. Long-term cultivation of this tissue can reverse diabetes.

[0031] It can be seen that the prior art generally believes that cell therapy for diabetes is mainly due to the regeneration of pancreatic islet cells. When studying diabetes, those skilled in the art generally take pancreatic islet cells as a research target.

[0032] The inventors overcame the technical prejudice in this field and surprisingly found that transplanting pancreatic mesenchymal stem cells into animals can treat diabetes by regenerating pancreatic exocrine glands rather than islet cells, and the treatment is very significant.

[0033] In some embodiments, the inventors have found that PMSCs express high levels of IL-6 by inhibiting IL-17 to improve the pancreatic immune microenvironment, thereby rescuing damaged islet cells. In addition, we used a knockout mouse model to show that lack of IL-6 leads to increased severity of STZ-induced type 1 diabetes and resistance to treatment with PMSC implantation, thus confirming that PMSCs act on IL-6 to protect β cells.

[0034] In some embodiments, the mesenchymal stem cells are isolated mesenchymal stem cells.

[0035] In some embodiments, the mesenchymal stem cells are directly implanted without treatment. In the current prior art, when mesenchymal stem cells are used to treat diabetes, the mesenchymal stem cells are generally first treated and activated in vitro. For example, when BEHROUS DAVANI et al. studied the use of human pancreatic islet-derived mesenchymal stem cells for the treatment of type I diabetes, they obtained cells from the pancreatic islets, used growth medium for in vitro amplification, and added differentiation induction solution to the amplified mesenchymal stem cells for induction (the induction solution ingredients are as follows: CMRL-1066 culture medium added with 2mM L-glutamine, 1% (wt / vol) bovineserum albumin (BSA), Fraction V FattyAcid Free (MP Biomedicals, Irvine, CA, http: / / www.mpbio.com), and 1×insulin-transferrinselenium-A (Gibco)). After 4 days of induction, mesenchymal stem cells formed epithelial cell clusters, which were transplanted under the renal capsule to form islet-like cell aggregates (BEHROUS DAVANI, et al. Human Islet-Derived Precursor Cells Are MesenchymalStromal Cells That Differentiate and Mature to Hormone-Expressing Cells InVivo. Stem Cells, 2007, 25: 3215-3222.). For example, Daisong Wang et al. used flow cytometry to sort Procr + Pancreatic stem cells and endothelial cells are co-cultured and expanded in vitro for a period of time and then implanted into the body to form pancreatic islet tissue, which is then transplanted into mice to reverse diabetes (Daisong Wang, et al. Long-Term Expansion of Pancreatic Islet Organoids from Resident Procr+Progenitors. Cell, 2020, 180: 1198–1211.).

[0036] The present invention can directly digest the mesenchymal stem cells conventionally cultured in vitro into single free cells, and then directly implant them into the animal body to achieve the therapeutic effect. It has very good operability and is easy to promote and use.

[0037] In some embodiments, the mesenchymal stem cells can be mixed with scaffold materials such as gelatin sponge.

[0038] In some embodiments, the present invention provides a method for treating diabetes, comprising the following steps: (1) culturing mesenchymal stem cells with culture medium; (2) removing the culture medium of the mesenchymal stem cells in step (1) and collecting the mesenchymal cells; (3) suspending the mesenchymal stem cells collected in step (2) with PBS or physiological saline (but not limited thereto), and implanting them under the kidney capsule, subcutaneously or on the mesentery of an animal, thereby achieving a therapeutic effect.

[0039] In some embodiments, the components of the culture medium in step (1) include FBS, glutamine (200 mM), 2-ME and α-MEM.

[0040] In some embodiments, the components of the culture medium in step (1) include FBS, penicillin / streptomycin solution, glutamine (200 mM), 2-ME (55 mM), and α-MEM.

[0041] In some embodiments, the mesenchymal stem cells are cultured to passages P1-P3, but are not limited thereto. BRIEF DESCRIPTION OF THE DRAWINGS

[0042] Figure 1 shows the identification of mouse PMSCs. (A) Flow cytometry analysis confirmed that CD105 + PMSCs co-expressed β-cell marker insulin, acinar cell marker amylase, ductal cell marker CK19, and pancreatic progenitor cell markers Ngn 3, Ptf1a, Hnf1β, PDX1, and Nkx6.1. (B) Flow cytometry analysis showed that PMSCs expressed mesenchymal stem cell surface markers Sca-1, CD105, CD73, and CD44, while blood cell markers CD34 and CD45 were negative. (C, D) PMSCs have osteogenic and adipogenic differentiation potentials, n = 3. (E) PMSCs showed the ability to form CFU-F and had a higher proliferation rate than BMMSCs, n = 3. (F) Immunofluorescence staining showed CD105 + PMSCs expressed islet cell marker insulin, pancreatic exocrine gland cell marker amylase, duct cell marker CK19, pancreatic progenitor cell markers Ngn3, Ptf1a, Hnf1β, PDX1 and Nkx6.1. (G) Flow cytometry analysis showed that PMSCs expressed mesenchymal stem cell surface marker CD44, and co-expressed β cell marker insulin, acinar cell marker amylase and pancreatic progenitor cell markers Ngn 3, Ptf1a, Hnf1β, PDX1 and Nkx6.1.

[0043] Figure 2 shows pancreatic stem cells regenerating ectopic exocrine pancreas. (A) H&E staining and immunofluorescence staining of ectopic regenerated pancreas in wild-type mice. (B) Representative H&E and immunofluorescence images show that PMSCs implanted under the renal capsule in wild-type mice ectopically regenerated exocrine pancreas, which contained a limited number of insulin-positive cells. Scale bar, 500 μm. (C, D) Representative H&E and immunofluorescence images show that PMSCs implanted under the renal capsule in immunodeficient mice ectopically regenerated exocrine pancreas, which contained a limited number of insulin-positive cells. Immunofluorescence showed that both insulin and amylase were double-stained in the ectopic regenerated pancreas. The right image is a higher magnification view of the immunostained image from the boxed area in the left H&E image. The black dotted line indicates the junction of the kidney and the regenerated exocrine pancreas. The yellow dotted line indicates the exocrine pancreatic acini. Kidney: kidney, EP: ectopic pancreas. (E) H&E and immunofluorescence staining of normal and ectopic regenerated pancreas in wild-type mice. H&E staining of the ectopic regenerated pancreas shows typical staining of the exocrine pancreatic compartment, similar to that of the normal pancreas. Immunofluorescence assays showed that the ectopic regenerated pancreas was negative for endocrine cell markers, such as insulin for β cells, glucagon for α cells, somatostatin for δ cells, and pancreatic polypeptide for PP cells; but was positive for acinar and ductal cell markers, such as amylase, trypsin, pancreatic lipase, and CK19. The right image is a higher magnification view of the boxed area in the left H&E and immunostaining images. The white dashed line indicates the junction of the kidney and the regenerated exocrine pancreas. The yellow dashed line indicates the exocrine pancreatic acini. The black dashed line indicates the duct. EP: ectopic pancreas. Scale bar, low magnification, 200 μm, high magnification, 50 μm. (F) Quantitative analysis showed that 80.0% of the implanted PMSCs regenerated the exocrine pancreas under the renal capsule; only 12.5% ​​of insulin-positive cells were detected in the regenerated exocrine pancreas. All results are representative of data generated from at least three independent experiments.

[0044] Figure 3 shows that PMSCs-mediated subrenal pancreatic regeneration improves STZ-induced type 1 diabetes. (A) Subrenal PMSCs implantation significantly reduced blood glucose levels in type 1 diabetic mice compared with the BMMSC implantation group. Wild-type mice were induced to diabetes by multiple low-dose streptozotocin (STZ, five doses of 50 mg / kg body weight) injections. Blood glucose levels of mice in the indicated groups were measured using tail vein blood samples (n=5). (B) PMSC implantation rescued glucose clearance ability. Glucose clearance ability of mice was measured using intraperitoneal glucose tolerance test (IPGTT) 2 months after implantation, n=3. (C,D) PMSC implantation enhanced serum C-peptide and insulin levels. Blood C-peptide and insulin levels were measured by ELISA 2 months after implantation, n=5. (E) Representative H&E and immunofluorescence images show that subrenal PMSCs implantation regenerated ectopic exocrine pancreas in type 1 diabetic mice, and no insulin-positive cells were detected in the regenerated pancreas. (F) PMSC implantation significantly improved the survival rate of immunodeficient mice with type 1 diabetes induced by a single high-dose injection of STZ (200 mg / kg body weight). Kaplan-Meier survival analysis of diabetic mice showed that PMSC implantation significantly improved the lifespan of mice compared with BMMSC implantation (n=4 for STZ and BMMSC-KC groups, n=5 for PMSC-KC group). (G) PMSC implantation significantly reduced blood glucose levels in type 1 diabetic mice. Blood glucose levels of each mouse in the designated group were measured by collecting tail vein blood samples for implantation (n=4 for STZ and BMMSC-KC groups, n=5 for PMSC-KC group). (H) PMSC implantation rescued glucose clearance ability. Glucose clearance ability of mice was measured using intraperitoneal glucose tolerance test (IPGTT) 2 months after implantation, n=3. (I) Representative H&E and immunofluorescence images showed that subrenal capsule implantation of PMSCs could regenerate an ectopic exocrine pancreas in which no insulin-producing cells could be detected in type 1 diabetic mice. KC: Subrenal implantation of MSCs. (JL) Subrenal implantation of PMSCs in the kidney capsule achieved greater improvements in glucose clearance, serum C-peptide, and insulin levels compared with systemic infusion of PMSCs. Blood glucose levels were measured during the IPGTT test 2 months after implantation, n=3. Blood C-peptide levels were measured by ELISA 2 months after implantation, n=5. (M) Subrenal implantation of PMSCs in the kidney capsule produced long-term glycemic improvements in type 1 diabetic mice compared with systemic infusion of PMSCs via the tail vein. Blood glucose levels of mice in the indicated groups were measured using tail vein blood samples (n=5). PMSC-systemic: systemic infusion of PMSCs. Scale bar, 50 μm. All results represent data generated in at least three independent experiments. Error bars = mean ± SD.Data were analyzed using two-way ANOVA with Dunnett's test or one-way ANOVA with Bonferroni correction to compare multiple groups. Within a group, each time point was compared to the time = 0 group; between groups, each group was compared to the STZ group. NS, no statistical difference. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

[0045] FIG4 shows that subrenal implantation of PMSCs can rescue the damaged orthotopic pancreas / islets in type 1 diabetic mice. (A) Representative H&E images of orthotopic pancreas / islets in type 1 diabetic mice that received subrenal implantation of PMSCs. The black dashed line indicates the islets in the pancreas of type 1 diabetic mice. (B) Immunofluorescence staining shows co-staining of insulin and amylase in the pancreas from type 1 diabetic mice. The black dashed line indicates the islets in type 1 diabetic mice. (C) Co-staining of Ki67 and insulin shows that implantation of PMSCs significantly increased the proliferation of damaged pancreatic β cells in type 1 diabetic mice. (D) Representative H&E images show that subrenal implantation of PMSCs can greatly rescue the damaged pancreatic islets in type 1 diabetic mice compared with systemic infusion of PMSCs. The right figure shows the quantification of islet area, n=5. (E) Immunofluorescence staining shows co-staining of insulin and amylase in the pancreas of type 1 diabetic mice. The black dashed line indicates the islets in the pancreas of type 1 diabetic mice. The right figure shows the quantification of insulin-positive cells, n=5. (F) Co-staining of Ki67 and insulin showed that PMSCs significantly enhanced the impaired proliferation of pancreatic β cells in type 1 diabetic mice compared with systemic infusion of PMSCs. The right panel shows the quantification of Ki67 and insulin double-positive cells, n = 5. PMSC-KC: subrenal capsule implantation of PMSCs, PMSC-systemic: systemic infusion of PMSCs. All results represent data generated from at least three independent experiments. Data were analyzed using two-way ANOVA with Dunnett's test or one-way ANOVA with Bonferroni correction to compare multiple groups. Within a group, each time point was compared with the time = 0 group; between groups, each group was compared with the STZ group (a, b, f, g). NS, not statistically significant. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

[0046] Fig. 5 is the co-staining of pancreatic exocrine gland-specific markers trypsin and pancreatic lipase with β-cell marker insulin. (A, B) Immunofluorescence staining shows co-staining of insulin with acinar cell markers trypsin and pancreatic lipase in the pancreas of type 1 diabetic mice. Compared with BMMSCs implantation or systemic infusion of PMSCs, the subrenal capsule implantation of PMSCs can significantly rescue STZ-induced damaged insulin-positive β cells and trypsin and pancreatic lipase-positive acinar cells. Scale bar, 50 μm. All results represent data generated in at least three independent experiments.

[0047] Figure 6 shows that PMSCs express high levels of IL-6 to protect pancreatic β cells. (A) The level of IL-6 secreted by PMSCs is significantly higher than that of BMMSCs. Cytokine array analysis of culture supernatants from mouse PMSCs and BMMSCs. Equal volumes of PMSC and BMMSC culture supernatants were taken for cytokine array (n=3). (BD) ELISA, PCR and Western blot analysis confirmed that PMSCs expressed higher levels of IL-6 than BMMSCs.

[0048] Figure 7 Representative immunofluorescence images show that IL-6 knockout PMSCs implanted under the renal capsule cannot rescue damaged primary islets in type 1 diabetic mice (such as insulin and Ki67 staining). The black dashed line indicates the islets. The right image is the marker + Quantification of cells, n = 5. Scale bar, 200 μm, low magnification.

[0049] Figure 8 shows that PMSCs express high levels of IL-6 to protect β cells. (A) Flow cytometry analysis showed that most CD105 + PMSCs express IL-6. (B) Immunostaining of pancreatic tissue showed that IL-6 was detected in both exocrine and endocrine tissues. (C,D) PMSCs protected MIN6β cells from STZ-induced apoptosis in vitro. After 24 h of STZ treatment at 5-10 mg / mL, MIN6β cells were co-cultured with PMSCs or BMMSCs. Apoptosis of MIN6 cells was measured by labeling with annexin V and 7AAD, n=3. Representative flow cytometric images gated on live (C) or apoptotic (D) MIN6β cells cultured for 24 h. MIN6 group: MIN6β cells were treated with STZ for 24 h and then continued to be cultured; PMSC+MIN6: MIN6β cells were treated with STZ for 24 h and then co-cultured with PMSCs; BMMSC+MIN6: MIN6β cells were treated with STZ for 24 h and then co-cultured with BMMSCs (direct contact, BMMSCs have a killing effect on β cells).

[0050] Figure 9 explores the key role of IL-6 in PMSC-mediated therapy of STZ-induced diabetic mice. (A, B) Compared with wild-type PMSC implantation, subrenal implantation of IL-6 knockout PMSCs failed to improve the type 1 diabetic phenotype. The glucose clearance ability of mice was tested using an intraperitoneal glucose tolerance test (IPGTT) 1 month after implantation, n = 3. Blood glucose levels of mice in the designated groups were measured over time using tail vein blood samples. (C) Subrenal implantation of IL-6 knockout PMSCs locally regenerated acinar structures, and intracellular scattered basophilic acinar-like cells could be detected. (D, E) Histological and immunostaining analysis further confirmed that IL-6 knockout PMSC implantation could not rescue the damaged islets and the number of insulin-positive cells in the pancreatic tissue of STZ-induced diabetic mice.

[0051] Fig.10 PMSCs expressed high levels of IL-6 to protect β cells. IL-6 knockout PMSCs had a reduced ability to protect MIN6 β cells from STZ-induced apoptosis in vitro. MIN6 β cells were co-cultured with wild-type or IL-6 knockout PMSCs after 5-10 mg / ml STZ treatment for 24 h. Apoptosis of MIN6 cells was measured by labeling with annexin V and 7AAD using flow cytometry.

[0052] Figure 11 shows that PMSCs implanted under the renal capsule increased the level of IL-6. (A) PMSCs implanted under the renal capsule expressed high levels of IL-6. Representative immunofluorescence staining showed strong IL-6 immunostaining in the wild-type PMSCs implantation group. No IL-6 staining was observed in the IL-6 knockout PMSCs implantation group. (B) ELISA analysis showed that serum IL-6 levels increased 2 and 4 weeks after PMSCs implantation. The dotted line represents the basal serum IL-6 level of control group mice. (C) Implantation of IL-6 knockout PMSCs failed to inhibit the level of IL-17. Among them, ELISA method was used to analyze IL-10, IL-17, TGF-β and IL-6 in the in situ pancreas 4 weeks after implantation. (D) Implantation of IL-6 knockout PMSCs failed to inhibit the activation of Th17 cells in the system of type 1 diabetic mice. Flow cytometric analysis showed that the spleen CD4 + IL-17 + Th17 cells and CD4 + CD25 in T cells + Foxp3 + Treg cells. All results represent data generated from at least three independent experiments.

[0053] Figure 12 shows that IL-6 knockout mice show resistance to PMSCs implantation therapy. (AB) The severity of STZ-induced type 1 diabetes in IL-6 knockout mice increases and becomes resistant to PMSC implantation therapy. (C, D) Representative H&E images of the host in situ pancreas / islets after type 1 diabetes IL-6 knockout mice receive PMSCs implanted under the renal capsule. All results represent data generated in at least three independent experiments. Error bars = mean ± SD. Data were analyzed using one-way ANOVA and Bonferroni correction or independent unpaired two-tailed Student's t-test. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

[0054] Fig.13 (A) Compared with the group with BMMSC implantation alone, the group treated with BMMSC implantation and intraperitoneal injection of cytokine IL-6 showed a more significant reduction in blood glucose. Wild-type mice were induced to diabetes by multiple low-dose streptozotocin (STZ, five doses of 50 mg / kg body weight) injections. In addition to the implantation of BMMSCs under the renal capsule, mice in the BMMSC+IL-6 group were given four consecutive intraperitoneal injections of IL-6 (2 ng / ml, 200 μl per mouse per injection) on the day of MSC transplantation and every week thereafter. Blood glucose levels of mice in the indicated groups were measured using tail vein blood samples at the time points indicated in the figure, n=4. (B) Compared with the group with BMMSC implantation alone, the group treated with BMMSC implantation and intraperitoneal injection of cytokine IL-6 showed a stronger ability to clear glucose. The ability of mice to clear glucose was tested using an intraperitoneal glucose tolerance test (IPGTT) 1 month after implantation, n=3. DETAILED DESCRIPTION

[0055] The technical solution of the present invention is further described below by specific embodiments, which do not limit the protection scope of the present invention. Some non-essential modifications and adjustments made by others based on the concept of the present invention still fall within the protection scope of the present invention.

[0056] “Soil saves seeds” strategy: Although pancreatic exocrine gland-derived mesenchymal stem cells (PMSCs) express multiple pancreatic progenitor cell markers, including PDX1, Nkx6.1, and Ngn3, when implanted into the kidney capsule, they mainly regenerate the pancreatic exocrine gland (soil), with only very few insulin-secreting cells (seeds) in the regenerated tissue. These ectopic PMSC implants do not produce insulin but are able to improve the type 1 diabetes phenotype by rescuing damaged recipient β cells. Mechanistically, we found that PMSCs improve the pancreatic immune microenvironment (soil) by expressing high levels of IL-6 to suppress IL-17, thereby rescuing damaged pancreatic β cells (seeds). In addition, we found that kidney capsule implantation of PMSCs showed significant and sustained therapeutic effects in STZ-induced mice compared with intravenous injection of PMSCs. PMSC-mediated exocrine pancreas regeneration rescues damaged pancreatic β cells in type 1 diabetic mice. This study reveals the important role of exocrine pancreatic regeneration in protecting β cells and provides a new “soil saves seeds” strategy for the treatment of type 1 diabetes.

[0057] "STZ" stands for streptozotocin.

[0058] The "trypsin" and "pancreatic lipase" are pancreatic exocrine gland-specific markers, and the "insulin" is a β-cell marker.

[0059] The acinar and ductal cell markers include amylase, trypsin, pancreatic lipase and CK19.

[0060] The experimental methods corresponding to the experimental result figures below are all carried out according to commercial kits or standard experimental procedures of the prior art unless otherwise specified. Examples of relevant experimental methods are described below. The experimental technical methods involved in the following embodiments are universal unless otherwise specified.

[0061] Experimental animals: Female C57BL / 6J, NU / j, NOD / SCID, IL-6 knockout, mice were used for this experiment. Age-matched female mice aged 8 to 10 weeks with the same background were used in all experiments. All animal experiments were performed according to institutionally approved protocols for animal research (SYSU-IACUC#2020000122, Sun Yat-sen University and IACUC#805478, University of Pennsylvania). Mice were euthanized at the time shown in each experiment after MSC implantation. In order to destroy endogenous pancreatic islet cells to induce type 1 diabetes, streptozotocin (STZ) was injected intraperitoneally (ip) with a single high dose of 200 mg / kg body weight or a bottom dose of 50 mg / kg for five consecutive days. STZ was dissolved in 0.01 M sodium citrate at pH 4.5 and injected into 8-week-old mice. Using an Optium Xceed blood glucose meter, blood samples were taken from the tail vein of mice to measure circulating glucose levels. Two consecutive measurements of non-fasting blood glucose ≥ 300 mg / dl are considered to indicate significant diabetic features (77). For the intraperitoneal glucose tolerance test (IPGTT), animals were fasted for 5 hours and then injected intraperitoneally. A 20% glucose solution (2 grams of glucose per kilogram of body weight) was injected. Blood glucose was measured at 0, 30, 60, 90 and 120 minutes after injection.

[0062] Flow cytometry:

[0063] For CD4, Foxp3 staining, spleen cells were harvested and stained with anti-CD4-PerCP and CD25-APC antibodies on ice for 30 minutes. Next, cells were stained with anti-Foxp3-PE antibodies using Foxp3 staining buffer kit (eBioscience, San Diego, California, the United States) to fix and permeabilize cells. For cytokine staining such as IL-17A, spleen cells were treated with 500ng / ml PMA and 500ng / ml ionomycin (Peprotech, Rocky Hill, NJ, the United States) for 5 hours, and brefeldin A (BFA; 5 μg / ml, Peprotech) was added, within the last 4 hours of cultivation. Subsequently, cells were stained with anti-CD4-PerCP antibodies, and then stained with anti-IL17APE antibodies using staining buffer kit. All antibodies were purchased from BioLegend (San Diego, California, USA). Samples were analyzed with FACScalibur flow cytometer (BD Bioscience, SanJose, CA, USA).

[0064] Histology:

[0065] The dissected pancreas and kidney samples were fixed in 4% paraformaldehyde (Sigma-Aldrich) and then embedded in paraffin. Paraffin sections (5 μm) were stained with hematoxylin and eosin (H&E). For immunohistochemical staining, paraffin-embedded sections were blocked with 5% BSA, incubated with primary antibodies against IL-6 at 4°C overnight, and then stained using the VECTASTAIN UNIVERSAL Elite ABC kit and the ImmPACT VIP peroxidase substrate kit (VECTOR) according to the manufacturer's instructions.

[0066] Immunofluorescence:

[0067] To prepare cryosection samples, the dissected pancreas was fixed in 4% PFA at 4°C for 4 hours, washed 3 times with PBS, and then embedded in optimal cutting temperature (OCT) compound. Tissue sections were incubated with primary antibodies overnight at 4°C, then washed in PBST (PBS + 0.1% Triton X-100), incubated with secondary antibodies and DAPI for 2 hours at room temperature, then washed and fixed for confocal imaging. For whole-wall staining, islets were fixed in 4% PFA at 4°C for 1 hour, washed 3 times with PBS, and then blocked with whole-wall blocking buffer for 1 hour at room temperature. The blocking buffer contained 10% FBS in PBST. The primary antibody was diluted in blocking buffer and incubated overnight at 4°C, then washed 3 times with PBST, and then incubated with secondary antibodies and DAPI overnight at 4°C. Photos were taken using a laser confocal microscope.

[0068] Cytokine array analysis and enzyme-linked immunosorbent assay (ELISA).

[0069] The levels of various cytokines and C-peptide in serum and tissue samples of mice were measured using ELISA kits purchased from R&D Systems (Minneapolis, MN, USA) according to the manufacturer's instructions.

[0070] Cytokine array analysis. Equal volumes of BMMSCs and PMSCs were analyzed using the Mouse Cytokine Array Panel A Array Kit (R&D Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. The results were scanned and analyzed using Image J software to calculate the blot intensity.

[0071] Western blotting:

[0072] Cells were lysed in protein extraction reagent (Thermo, Waltham, MA, USA) containing protease and phosphatase inhibitors (Roche, Basel, Switzerland), and protein concentration was determined using a protein concentration assay (Bio-Rad Laboratories, Hercules, CA, USA). 20 μg of protein was separated using vertical electrophoresis on SDS-PAGE gels and transferred to 0.2 μm nitrocellulose membranes (Millipore, Burlington, MA, USA). The membrane was blocked with 5% nonfat dry milk and 0.1% Tween-20 for 1 hour, and then the primary antibody was diluted in blocking solution overnight according to the manufacturer's instructions. The membrane was then incubated in HRP-conjugated secondary antibody (Santa Cruz) diluted 1:10,000 in blocking solution for 1 hour at room temperature. SuperSignal West Pico chemiluminescent substrate (Thermo) and Bio-Rad ChemiDoc TM Protein expression was detected by imager (Hercules, CA, USA).

[0073] Real-Time PCR:

[0074] Total RNA was isolated and extracted from different cells using TRIzol kit (Life Technologies, Invitrogen). RNA samples (1 μg) were reverse transcribed in a reverse transcription system (QIAGEN). The primers used in the PCR experiment were: mouse IL-6 upstream primer GGCGGATCGGATGTTGTGAT, downstream primer GGACCCCAGACAATCGGTTG. PCR conditions were: 95°C 5 minutes, (95°C 10 seconds, 50°C 45 seconds) × 40 and 90°C 10 seconds.

[0075] In vitro CD4+IL-17A+Th17 cell induction:

[0076] BD Imaging was used according to the manufacturer's instructions. TMCD4+ T lymphocytes were isolated from spleen cells using anti-mouse CD4 Particles-DM (BD Bioscience). CD4+ T cells were pre-stimulated for 2 days with culture plates conjugated with anti-CD3e antibodies (clone 145-2C11, 5 μg / ml, BioLegend) and soluble anti-CD28 antibodies (clone 37.51, 5 μg / ml, BioLegend). For the induction of Th17 cells (T helper 17 cells), activated T cells (1×106) were added to 0.2×106 MSCs with recombinant human TGF-β1 (2 μng / ml; R&D Systems, Minneapolis, MN, USA), mouse IL-6 (25 μng / ml; Peprotech), recombinant mouse IL-23 (20 μng / ml; Peprotech), and recombinant mouse IL-β1 (20 ng / ml; Peprotech) (89). After 3 days, cells in suspension were collected for IL-17A antibody staining and analyzed using FACScalibur (BD Bioscience).

[0077] Example 1 Isolation, culture and identification of pancreatic mesenchymal stem cells (PMSCs)

[0078] The steps of isolation and culture include:

[0079] The pancreatic tissue of mice was gently isolated, minced, and digested with phosphate buffered saline (PBS) containing 2 mg / mL type I collagenase (Worthington Biochemical, Lakewood, NJ, USA) and 4 mg / mL Dispase II (Roche Diagnostics, Basel, Switzerland) at 37°C for 1 hour. The cell suspension obtained by digestion was passed through a 70 μm filter (BD Biosciences, San Jose, California, USA) to obtain a single cell suspension of the pancreas. All nucleated cells (ANC) were seeded into 100 mm culture dishes, and the complete medium contained α-MEM (Invitrogen), supplemented with 20% FBS, 2 mM L-glutamine (Invitrogen), 55 μM 2-mercaptoethanol (Invitrogen), 100 U mL -1 Penicillin and 100 μg mL -1 Streptomycin (Invitrogen) was then incubated at 37°C and 5% CO 2 The culture was incubated for 48 hours at 4 °C. The culture was washed twice with PBS to remove non-adherent cells. The adherent cells were cultured for another 12 days in the above complete medium under the same conditions.

[0080] PMSCs were further characterized and demonstrated to have the ability of self-renewal (assessed by CFU-F) and high proliferation rate (assessed by BrdU staining):

[0081] (1) Flow cytometry analysis confirmed that these pancreatic tissue-derived CD105 + PMSCs co-expressed β-cell marker insulin, acinar cell marker amylase, pancreatic progenitor cell markers CK19, and pancreatic progenitor cell markers Ngn 3, Ptf1a, Hnf1β, PDX1, and Nkx6.1. Figure 1A In addition, flow cytometry analysis confirmed that these pancreatic tissue-derived MSCs positively expressed mesenchymal stem cell surface markers CD44, CD105, CD73 and Sca-1, but did not express blood cell markers CD34 and CD45 ( Figure 1B ).

[0082] (2) These MSCs also show multipotential differentiation capabilities, including osteogenic, adipogenic ( Figure 1C , 1D), the osteogenic induction and staining steps are as follows:

[0083] 1) Culture with regular culture medium until cell confluence; 2) Replace osteogenic medium 2-3 times a week for 4 weeks or longer; 3) When mineralized nodules are observed, stain with Alizarin Red S; 4) Protein collection time is 1 week after induction; 5) Dissolve 1g Alizarin Red S in 100ml distilled water; 6) Filter through a 0.22um filter and store at room temperature; Wash the culture dish twice with PBS; 7) Fix with 60% isopropanol at room temperature for 1 minute; 8) Rehydrate with distilled water for 2-3 minutes; 9) Stain with staining solution at room temperature for 3 minutes; 10) Wash the culture dish with distilled water several times; 11) Dry and observe under a microscope, and use Image J software to calculate the osteogenic positive area.

[0084] Among them, adipogenic induction and staining were also carried out according to the standard experimental procedures of the commercial kit. (3) Self-renewal ability evaluated by CFU-F ( Figure 1E Left side) and cell proliferation rate assessed by BrdU staining ( Figure 1E The experimental method for CFU-F evaluation is as follows: 1) 5×10 isolated pancreatic cells were inoculated into a 60 mm culture plate. 3 ANC;

[0085] 2) After 14 days, the culture plates were stained with a mixture of 0.1% toluidine blue and 2% paraformaldehyde solution;

[0086] 3) Count clones containing >50 cells as a single clone cluster and perform CFU-F counting.

[0087] The steps of BrdU labeling are as follows: 1) Cells were labeled with 1×10 5 / mL cells were seeded in a 12-well plate (with a cover glass placed inside), cultured for 1 day, and synchronized with a culture medium containing 0.4% FBS for 3 days to make most of the cells in the G0 phase;

[0088] 2) Before terminating the cell culture, add BrdU (final concentration 30 μg / L) and incubate at 37°C for 40 min;

[0089] 3) Discard the culture medium and wash the slides three times with PBS;

[0090] 4) Methanol / acetic acid fixation for 10 min;

[0091] 5) The fixed slides were air-dried and 0.3% H 2 O 2 -Methanol for 30 min to inactivate endogenous oxidases.

[0092] 5% BSA blocking;

[0093] 6) Denaturing nucleic acid in denaturing solution for 5 minutes;

[0094] 7) After cooling in an ice bath, wash with PBS and add the primary antibody, i.e. anti-mouse BrdU monoclonal antibody;

[0095] 8) Fluorescent secondary antibody staining: the total number of cells and the number of BrdU-positive cells in 5 high-power fields were randomly counted under a microscope, and the positive rate was calculated.

[0096] The test results show that PMSCs have stronger CFU-F formation and proliferation ability, stronger osteogenic differentiation ability and lower adipogenic differentiation ability compared with BMMSCs. Similar to BMMSCs, PMSCs express MSC positive surface markers Sca-1, CD105, CD44, CD73 but do not express blood cell surface markers CD34 and CD45.

[0097] Immunofluorescence staining showed that pancreatic exocrine gland-derived MSCs (PMSCs) expressed mature islet-specific markers, including insulin, as well as mature exocrine gland marker amylase and ductal cell marker cytokeratin 19 (CK19) ( Figure 1F In addition, flow cytometry analysis ( Figure 1A , 1G), immunofluorescence staining (S1B), PMSCs expressed pancreatic progenitor cell markers PDX1, Nkx6.1, as well as endocrine differentiation marker Ngn 3, acinar differentiation marker Ptf1a and ductal differentiation marker Hnf1β. Interestingly, flow cytometry showed that up to 71.11% of CD105 + PMSCs expressed the exocrine marker amylase, whereas only 11.52% of CD105 + PMSCs express insulin ( Figure 1A ). These data showed that PMSCs had a lower proportion of insulin-positive cells and a higher proportion of amylase-positive cells, suggesting that PMSCs express markers of mature pancreatic tissue as well as differentiated cells and progenitor cells, but they exhibit an exocrine-dominant phenotype.

[0098] PMSCs have general MSC characteristics, including the expression of MSC surface molecules and the ability to self-renew and multipotent differentiation. Our test results show that compared with bone marrow MSCs (BMMSCs), PMSCs have the ability to form colonies (CFU-F) and have a higher proliferation rate ( Figure 1E Flow cytometric analysis confirmed that PMSCs positively expressed mesenchymal stem cell surface markers CD44, CD73, CD105 and Sca-1, and negatively expressed blood cell markers CD34 and CD45 ( Figure 1B PMSCs also show multipotential differentiation capabilities, including osteogenic and adipogenic differentiation ( Figure 1C , 1D ).

[0099] Example 2 Pancreatic mesenchymal stem cells were implanted into mice under the kidney capsule

[0100] Pancreatic mesenchymal stem cells were cultured and expanded in a 10 cm cell culture dish. The medium was routinely changed until the cells were in contact and fused. The culture medium was discarded and digested into single cells. About 4×10 6 mesenchymal cells; suspend the cells with about 20μL 1×PBS solution and place them on ice for later use; or mix the above PBS cell suspension with a small piece of absorbable gelatin sponge and place the mixture on ice for later use. You can also choose to culture and expand pancreatic mesenchymal stem cells in a 10cm cell culture dish, change the medium regularly until the cells are in contact and fused, and continue to culture the cells for about 3-7 days to make the cell matrix thicker. Use a blunt tip or other method to peel off the attached PMSC from the culture dish as a whole, transfer it to a new 24-well plate for continued culture, and form PMSC pellets after 1-3 days. Place the PMSC pellets on ice for later use. (There is no significant difference in the regeneration results after implantation under the renal capsule in several ways.)

[0101] After the mice were anesthetized, the back skin was depilated, disinfected and prepared. A longitudinal incision of about 2 cm was made on the skin with surgical scissors to expose the kidney. An opening was made under the renal capsule with the tip of microsurgical scissors or microtweezers, and the renal capsule and the submembranous renal tissue were bluntly separated to make a pocket for the implant. The PMSC+gelatin sponge mixture or PMSC pellets were placed in the pocket under the renal capsule, or the PMSC cell suspension was injected under the renal capsule. The renal capsule wound was closed with an electric knife, the kidney was put back in place, and the surgical wound was sutured. The grafts were collected after 8 weeks for corresponding testing.

[0102] Example 3 Pancreatic stem cells ectopically regenerate the exocrine pancreas

[0103] When PMSCs were implanted under the renal capsule of wild-type or immunodeficient mice, they were able to ectopically regenerate pancreatic exocrine glandular tissue without endocrine islets 8 weeks after implantation ( Figure 2A -D). Similar to the normal exocrine pancreas, the regenerated exocrine pancreas is composed of typical acini and ducts ( Figure 2C -E,). The regenerating acini show strong basophilic staining of exocrine pancreatic cells with eosinophilic secretory granules and epithelial-like lining of the ducts ( Figure 2C -E). Immunofluorescence staining confirmed that the regenerated ectopic pancreas expressed the exocrine markers amylase, trypsin, and pancreatic lipase, as well as the ductal marker CK19 ( Figure 2E Approximately 80% of the PMSC implants exhibited exocrine pancreatic architecture, with only 12.5% ​​containing a small number of scattered insulin-producing β cells ( Figures 2A-2F Other types of endocrine cells, such as glucagon-producing α cells, somatostatin-producing δ cells, and pancreatic polypeptide-producing PP cells, were not detected in the implants. Figure 2A , 2E ). These data suggest that most PMSC-regenerated implants formed exocrine pancreases without significant insulin production.

[0104] Example 4 PMSC-mediated subcapsular pancreatic regeneration improves STZ-induced type I diabetes

[0105] To test the therapeutic effect of PMSC-regenerated ectopic exocrine pancreas on diabetes, we first induced type 1 diabetes in wild-type mice using multiple low-dose streptozotocin (STZ) injections. We compared the effects of PMSC and BMMSC implantation under the renal capsule and found that PMSC implantation, but not BMMSC implantation, significantly reduced blood glucose levels in type 1 diabetic mice ( Figure 3A ). In addition, PMSC implantation rescued the glucose clearance ability and increased the serum C-peptide and insulin levels compared with the BMMSC group ( Figure 3B-D). In the PMSC implantation group under the renal capsule of STZ-induced diabetic mice, regenerated exocrine acinar cells and acini were detected ( Figure 3E Immunofluorescence staining confirmed that ectopic pancreatic cells regenerated by PMSCs expressed the exocrine marker amylase ( Figure 3E ). To further confirm the therapeutic potential of PMSC implantation, we induced type 1 diabetes in immunodeficient mice using a single high-dose STZ injection. Consistent with the above results, we found that implantation of PMSCs, but not BMMSCs, significantly improved the survival rate of type 1 diabetic mice ( Figure 3F ). After PMSC implantation, the life span of diabetic mice was extended from 40 days to 120 days ( Figure 3F , Figure 3G ). The blood glucose level in the PMSC group was significantly reduced 60 days after implantation, but not in the BMMSC group ( Figure 3G , Figure 3H ). In addition, PMSC implantation rescued the glucose clearance ability compared with the BMMSC group ( Figure 3H ). These data suggest that PMSC engraftment is able to rescue the STZ-induced type 1 diabetic phenotype, which may be independent of insulin production.

[0106] To further confirm that PMSC-mediated exocrine pancreas regeneration can improve the phenotype of diabetes, we compared the efficacy of PMSCs implanted under the renal capsule with that of systemic infusion (tail vein injection in mice). Ectopic exocrine pancreas regeneration under the renal capsule was observed in the PMSC implantation group, but not in the systemic infusion group ( Fig. 3I ). Seven days after PMSC administration, blood glucose levels in both the PMSC subcapsular implantation group and the systemic reinfusion group decreased ( Figure 3J However, the PMSC subcapsular implantation group showed significant recovery of glucose clearance and increased serum C-peptide levels one month after treatment compared with the group receiving systemic reinfusion of PMSCs ( Figure 3K Interestingly, 40 days after PMSC administration, the subrenal capsule implantation group maintained the effect of improving blood glucose, but the systemic infusion group failed to maintain the reduction of blood glucose levels ( Figure 3M Our data demonstrate that PMSC subrenal capsule implantation-mediated ectopic exocrine pancreas regeneration has a significant and sustained therapeutic effect in STZ-induced type 1 diabetic mice compared with intravenous infusion.

[0107] Example 5: Subrenal implantation of PMSCs can rescue damaged pancreas / islets in situ in type 1 diabetic mice

[0108] To explore how PMSC-mediated ectopic exocrine pancreatic regeneration rescues the diabetic phenotype, we examined the orthotopic pancreas of STZ-induced diabetic mice. We found that PMSC implantation under the renal capsule significantly improved the histological structure of pancreatic islets in the orthotopic pancreatic tissue of mice, as assessed by H&E staining ( Figure 4A Immunostaining showed that the number of insulin-positive β cells and Ki67 and insulin double-positive proliferating β cells increased significantly ( Figure 4B , 4C). Similarly, the number of amylase, trypsin, and pancreatic lipase-positive acinar cells was significantly increased ( Figure 4B , Figure 5A ). The experimental results show that it is the implantation of PMSCs rather than BMMSCs that rescues STZ-induced damage to pancreatic β cells and acinar cells ( Figure 4A , 4B, 4C). PMSCs were not able to significantly improve the islet size, the number of insulin-positive cells, and the Ki67 / insulin double-positive proliferating β cells in pancreatic tissue after systemic injection ( Figure 4D -F, Figure 5B ). These data suggest that subrenal implantation of PMSCs can rescue STZ-induced primary pancreatic / islet tissue damage and demonstrate the feasibility of the “seeds rescued in soil” strategy for type 1 diabetes treatment.

[0109] Example 6 PMSCs express elevated levels of IL-6 to protect β cells

[0110] Cytokine array analysis, ELISA and PCR, Western blot detection ( Fig. 6A -D). We found that PMSCs significantly expressed IL-6 (an interleukin that can act as a pro-inflammatory or anti-inflammatory cytokine) compared with BMMSCs (Scheller, J., Chalaris, A., Schmidt-Arras, D. & Rose-John, S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 1813, 878-888, doi: 10.1016 / j.bbamcr.2011.01.034 (2011).). Immunostaining and flow cytometric analysis confirmed that most CD105-positive PMSCs expressed IL-6 ( Figure 7 , Fig. 8A Immunostaining analysis showed that IL-6 was expressed in both pancreatic islets and exocrine pancreas ( Figure 8B ). In addition, we found that PMSCs, but not BMMSCs, could protect the pancreatic β cell line MIN6 from STZ-induced apoptosis in an in vitro co-culture system ( Figure 8C , 8D).

[0111] We used PMSCs derived from IL-6 knockout mice for subrenal capsule implantation therapy and found that PMSCs derived from IL-6 knockout mice failed to improve the STZ-induced diabetic phenotype compared with the wild-type PMSC implantation group ( Figures 9A-9C IL-6 knockout PMSCs implanted under the renal capsule partially regenerated the alveolar structure, and basophilic acinar-like cells were detected, but their histological structure was different from that of normal acini, and fluorescent staining showed that amylase staining was scattered, not as uniform as PMSC regenerated tissue ( Fig. 9C ). Histological and immunostaining analyses further confirmed that IL-6 knockout PMSC implantation failed to rescue the damaged islets, insulin-positive cells, and pancreatic tissue in STZ-induced diabetic mice ( Figures 9D-9E In addition, the ability of IL-6 gene knockout PMSCs to resist MIN6β cell apoptosis was significantly reduced after treatment with STZ in vitro ( Fig.10 ).

[0112] Example 7 Implantation of PMSCs under the renal capsule increases IL-6 levels

[0113] Two weeks after transplantation, in the subcapsular grafts of STZ-induced diabetic mice, strong IL-6 staining was observed in the wild-type PMSC transplantation group, but no IL-6 expression was observed in the IL-6 knockout PMSC transplantation group ( Fig.11A Interestingly, implantation of wild-type, but not IL-6 knockout PMSCs under the renal capsule increased IL-6 levels in serum and in situ pancreas at 2 and 4 weeks after PMSC implantation, as shown by ELISA ( Fig. 11B ), indicating that PMSCs ectopically implanted under the renal capsule upregulated pancreatic and serum IL-6 levels. Next, we found that wild-type but not IL-6 knockout PMSC implantation suppressed IL-17 levels ( Fig. 12C ). Accordingly, implantation of IL-6 knockout PMSCs failed to rescue the alterations in Th17 / Treg cell levels in STZ-induced diabetic mice ( Fig.11D These data suggest that IL-6 is required for the pathway that improves the pancreatic immune microenvironment by inhibiting IL-17.

[0114] Example 8 IL-6 knockout mice show resistance to PMSC implantation therapy

[0115] We found that IL-6 knockout mice showed severe diabetic phenotypes under STZ-induced diabetic response, whereas ectopic PMSC transplantation failed to rescue the diabetic phenotype of IL-6 knockout mice ( Fig. 12A-D). H&E staining showed that pancreatic tissues from IL-6 knockout mice displayed similar structures to those of wild-type mice, but renal capsule PMSC implantation failed to rescue STZ-induced destruction of pancreatic β cells in knockout mice. These findings confirm the role of IL-6 in protecting β cells.

[0116] Example 9 Effect of IL-6 in the treatment of type 1 diabetes mellitus by subrenal transplantation of bone marrow mesenchymal stem cells

[0117] Wild-type mice were induced to be diabetic by multiple low-dose streptozotocin (STZ, five doses of 50 mg / kg body weight). In addition to implanting bone marrow mesenchymal stem cells (BMMSC) (4×10 6 In addition to 200 μL per mouse, IL-6 (2 ng / mL, 200 μL per mouse per injection) was given intraperitoneally four times on the day of BMMSC transplantation and every week thereafter. Fig.13 Blood glucose levels of mice in the indicated groups were measured using tail vein blood samples at the time points indicated in A, n = 4. Glucose clearance ability of mice was tested by intraperitoneal injection of glucose (IPGTT) 1 month after BMMSC implantation, n = 3.

[0118] Test results such as Fig.13 As shown in (A, B), we used bone marrow mesenchymal stem cells (BMMSC) to implant into the kidney capsule and injected cytokine IL-6 intraperitoneally. It was found that compared with the group of BMMSC implanted into the kidney capsule alone, the effect of BMMSC implanted into the kidney capsule and injected with cytokine IL-6 intraperitoneally in the treatment of STZ-induced diabetes was better ( Fig.13 A, 13B).

Claims

1. Application of IL-6 and mesenchymal stem cells in the preparation of drugs for treating / preventing diabetes, wherein the mesenchymal stem cells are derived from bone marrow; and the diabetes is type 1 diabetes.

2. The use according to claim 1, characterized in that The mesenchymal stem cells are free bone marrow mesenchymal stem cells.

3. The use according to claim 1, characterized in that The medicine is an injection preparation.

4. The use according to claim 1, characterized in that The mesenchymal stem cells are injected under the kidney capsule; and the IL-6 is injected intraperitoneally.

5. The use according to any one of claims 1 to 4, characterized in that: The drug also includes a pharmaceutically acceptable carrier.